 Vascular Biogenics Ltd NASDAQ: VBLT announces results from the independent Data Safety Monitoring Committee DSMC pre-planned review of the ongoing OVAL Phase 3 study of VB-111 in recurrent ovarian cancer. According to the results, the committee found no safety issues with the trial and recommended its continuation. 